text stringlengths 1 17.8k |
|---|
lK אhY7 YD h Y7
hK א¶jEא אX í [¥K í ¥Y/ ÎBj ¶K
h . |
٥٠٠٢í ، j@ jEA ¶K< אYW&א¹ ،¶K< אY1HBA .uא¹ MK א¥¹W א[Eo ¥ l<Ej ·uB! |
.EAq . |
£j ¹ j@ jE אK j>â í ·K C א·KK. |
- 17- d A&١א − א¥j;3 אMBoK? l¹W א¥KE<&א d A& ٢א− ªאYT אK>
x אUC ÐK< MEu
fX ١א− K:7C& אM K@& ME&K< אM¹W& א fX ٢א− אÎ BA l¹W א¥KE<& א fX ٣א− א¥Kt אאYx l¹W א¥KE<& א u 反对在体育运动中使用兴奋剂 国 际 公 约 巴黎，2005年10月19日 反对在体育运动中使用兴奋剂国际公约 联合国教育、科学及文化组织（以下简称“教科文组织”）大会在其 2005年10月... |
使用或企图使用某种禁用物质或禁用方法； 3. |
接到依照反兴奋剂规则授权的检查通知后，拒绝样品采集、无正当理由未能完成样品采集或者其他逃避样品采集的行为； 4. |
违反运动员接受赛外检查的义务，包括未按规定提供行踪信息，并错过根据合理规则通知的检查； 5. |
篡改或企图篡改兴奋剂控制过程中的任何环节； 6. |
持有禁用物质或禁用方法； 7. |
从事任何禁用物质或禁用方法的交易； 8. |
对任何运动员施用或企图对其施用 某种禁用物质或禁用方法，或者协助、鼓励、资助、教唆、掩盖使用禁用物质与方法的行为，或其他类型的违反反兴奋剂规则的串通行为或任何企图违规的行为。 (四) 就实施兴奋剂控制而言，“运动员”是指任何参与国际级或国家级（以每个国家反兴奋剂组织确定的，并为缔约国所接受的定义为准）体育运动的人，以及任何其他参与被缔约国选定的较低水平体育运动或赛事的人。 就教育与培训活动而言，“运动员”是指任何参与某个体育组织所管理的体育运动的人。 - 4 - (五) “运动员辅助人员”是指同运动员一起工作，或辅助运动员参加或准备体育比赛的任何教练、体能教练、领队、经纪人、运动队工作人员、官员、医疗或医护人员。 (六) 《条例》是... |
FAIT à Paris, le dix-huit novembre 2005, en de ux exemplaires authentiques portant la signature du Président de la 33e session de la Conférence gé nérale de l’UNESCO et du Directeur général de l’UNESCO. |
Ces deux exemplaires seront déposés dans les archives de l’UNESCO. |
HECHO en París, el 18 de noviembre de 2005, en dos ejemplares auténtic os que llevan la firma del Presidente de la Conferencia Ge neral de la UNESCO en su 33ª reunión y del Director General de la UNESCO, ejemplares que quedarán depositados en los archivos de la UNESCO. |
СОВЕРШЕНО в Париже восемнадцатого ноября 2005 года в двух аутентичных экземплярах , которые скреплены подписями Председателя 33-й сессии Генеральной конференции и Генерального директора ЮНЕСКО и сдаются на хранение в архив ЮНЕСКО . |
hY7 YD h Y7
hK א¶jEא אX í [¥K í ¥YlK/אÎBj ¶K
h ٥٠٠٢í ، ¶K< אYW&א¹ ،¶K< אY1HBA .uא¹ MK א¥¹W א[Eo¥ l<Ej ·uB! .EAq . j@ jEA . |
j@ jE אK j>â í ·K C א·KK £j ¹. |
2005年11月18日订于巴黎，一式两份，均为正本，由教科文组织大会第三十三届会议主席和该组织总干事签署，并存放于该组织的档案中。 The above text is the authentic text of the Convention hereby duly adopted by the General Conference of UNESCO at its 33rd sess ion, held in Paris and declared closed on the twenty-first day of October 2005. |
Le texte qui précède est le texte authenti que de la Convention dûment adoptée par la Conférence générale de l'UNESCO à sa 33e se ssion, qui s'est tenue à Paris et qui a été déclarée close le vi ngt et un octobre 2005. |
Lo anterior es el texto auté ntico de la Convención aproba da en buena y debida forma por la Conferencia General de la UNESCO en su 33ª reunión, celebrada en París y clausurada el veintiuno de octubre de 2005. |
Приведенный выше текст является подлинным текстом Конвенции , надлежащим образом принятой Генеральной конференцией ЮНЕСКО на ее 33-й сессии, которая состоялась в Париже и была объявлена закрытой двадцать первого октября 2005 года. |
i¥¹£ í j@ jEA ¶K< אY1H& אKWB
א× אMEK>u lAqT א ]C אj ¸u
£¥אj א]Cא MKאא¹ YD h hY7<א¹ »£K$ אí KDK אhA
×א¹ [¥K í W?<C&. |
אu µ¹T אhY7/Yj .٥٠٠٢ 上述文本为在巴黎召开的、于2005年10 月21日闭幕的教科文组织大会第三十三届会议通过的公约正式文本。 IN WITNESS WHEREOF the undersigned have signed this Convention this eighteenth day of November 2005. |
EN FOI DE QUOI ont apposé leurs signatures, le dix-huit novembre 2005. |
EN FE DE LO CUAL estampan sus firmas, en este día dieciocho de noviembre de 2005. |
В УДОСТОВЕРЕНИЕ ЧЕГО настоящую Конвенцию подписали восемнадцатого ноября 2005 года. |
¶W? K& KK¹ ¶jEא אX í MEK>t א¸X kA
¸K£ ·א¥jX& א·K8 7 אa¹ hK אY7
h lK אhY7 YD/ ÎBj.٥٠٠٢ 为此，我们于2005年11月18日在本公约签字，以昭信守。 President of the General Conference Le Président de la Conférence générale El Presidente de la Conferencia General Председатель Генеральной конференции ¶K< אY1H& א... |
All Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4 and S6(a) and Prohibited Methods M1, M2 and M3. |
SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S1. |
ANABOLIC AGENTS Anabolic agents are prohibited. |
S1.1 Anabolic Androgenic Steroids (AAS) (a) Exogenous* AAS, including: 1-androstendiol (5α-androst-1-ene-3 β,17β-diol ) ; 1-androstendione (5α-androst-1-ene-3,17-dione) ; bolandiol (19-norandrostenediol) ; bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione) ; calusterone; clostebol; danazol (17α-ethyn... |
(b) Endogenous** AAS when administered exogenously: Androstenediol (androst-5-ene-3 β,17β-diol) ; androstenedione (androst-4-ene-3,17-dione) ; dihydrotestosterone (17β-hydroxy-5α -androstan-3-one) ; prasterone (dehydroepiandrosterone, DHEA) ; testosterone and the following metabolites and isomers: 5α-androstane-3... |
[Comment to class S1.1(b): Where an anabolic androgenic steroid is capable of being produced endogenously, a Sample will be deemed to contain such Prohibited Substance and an Adverse Analytical Finding will be reported where th e concentration of such Prohibited Substance or its metabolites or markers and/or any o... |
A Sample shall not be deemed to contain a Prohibited Substance in any such case where an Athlete proves that the concentration of the Prohibited Substance or its metabolites or markers and/ or the relevant ratio(s) in the Athlete’s Sample is attributable to a physiolo gical or pathological condition. |
In all cases, and at any concentration, the Athlete’s Sample will be deemed to contain a Prohibited Substance and the laborator y will report an Adverse Analytical Finding if, based on any reliable analytical method (e.g. |
IRMS ), the laboratory can show that the Prohibited Substance is of exogenous origin. |
In such case, no further investigation is necessary. |
When a value does not so deviate from the ra nge of values normally found in humans and any reliable analytical method (e.g. |
IRMS) has not determined the exogenous origin of the substance, but if there are indications, such as a comparison to endogenous reference steroid profiles, of a possible Use of a Prohibited Substance, or when a laboratory has reported a T/E ratio greater than four (4) to one (1) and a ny reliable analytical me thod (... |
IRMS) has not determined the exogenous origin of the substance, further investigation shall be conducted by the relevant Anti-Doping Organization by reviewing the results of any previous test(s) or by conducting subsequent test(s). |
When such further investigation is required th e result shall be repor ted by the laboratory as atypical and not as adverse. |
If a laboratory re ports, using an additi onal reliable analytical method (e.g. |
IRMS), that the Prohibited Substance is of exogenous origin, no further investigation is necessary, and the Sample will be deemed to contain such Prohibited Substance. |
When an additional reliable analytical met hod (e.g. |
IRMS) has not been applied, and the minimum of three previous test results are not available, a longitudinal profile of the Athlete shall be established by performing three no adva nce notice tests in a pe riod of three months by the relevant Anti-Doping Organization . |
The result that triggere d this longitudinal study shall be reported as atypical. |
If the longitudinal profile of the Athlete established by the subsequent tests is not physiologically norma l, the result shall then be reported as an Adverse Analytical Finding . |
In extremely rare individual cases, boldenone of endogenous origin can be consistently found at very low nanograms per milliliter (ng/mL) le vels in urine. |
When such a very low concentration of boldenone is reported by a labo ratory and the application of any reliable analytical method (e.g. |
IRMS) has not determin ed the exogenous origin of the substance, further investigation may be c onducted by subsequent test(s). |
For 19-norandrosterone, an Adverse Analytical Finding reported by a laboratory is considered to be scientific and valid proof of exogenous origin of the Prohibited Substance . |
In such case, no further investigation is necessary. |
Should an Athlete fail to cooperate in the investigations, the Athlete ’s Sample shall be deemed to contain a Prohibited Substance .] |
For purposes of this section: * “exogenous” refers to a substance which is not ordinarily capabl e of being produced by the body naturally. |
** “endogenous” refers to a substance which is capable of being produced by the body naturally. |
S1.2. |
Other Anabolic Agents, including but not limited to: Clenbuterol, selective androgen receptor modu lators (SARMs), tibolone, zeranol, zilpaterol. |
S2. |
HORMONES AND RELATED SUBSTANCES The following substances and their re leasing factors, are prohibited: 1. |
Erythropoiesis-Stimulating Agents (e .g. |
erythropoietin (EPO), darbepoietin (dEPO), hematide); 2. |
Growth Hormone (GH), Insulin-like Growth Factors ( e.g. |
IGF-1), Mechano Growth Factors (MGFs); 3. |
Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) in males; 4. |
Insulins; 5. |
Corticotrophins and other substances with similar chemical structure or similar biological effect(s). |
[Comment to class S2: Unless the Athlete can demonstrate that the concentration was due to a physiological or pathological condition, a Sample will be deemed to contain a Prohibited Substance (as listed above) where the concentration of the Prohibited Substance or its metabolites and/or relevant ratios or markers in t... |
If a laboratory report s, using a reliable anal ytical method, that the Prohibited Substance is of exogenous origin, the Sample will be deemed to contain a Prohibited Substance and shall be reported as an Adverse Analytical Finding .] |
S3. |
BETA-2 AGONISTS All beta-2 agonists including their D- and L-isomers are prohibited. |
Therefore, formoterol, salbutamol, salmeter ol and terbutaline when administered by inhalation also require a Therapeutic Use Exem ption in accordance with the relevant section of the International Standard for Therapeutic Use Exemptions. |
. |
Despite the granting of a Therap eutic Use Exemption, the presence of salbutamol in urine in excess of 1000 ng/mL will be considered as an Adverse Analytical Finding unless the Athlete proves, through a controlled pharmacokinetic study, that th e abnormal result was the consequence of the use of a therap eutic dose of... |
S4. |
HORMONE ANTAGONISTS AND MODULATORS The following classes are prohibited: 1. |
Aromatase inhibitors including, but not limited to: anastrozole, letrozole, aminoglutethimide, exemestane , formestane, testolactone. |
2. |
Selective estrogen recept or modulators (SERMs) including, but not limited to: raloxifene, tamoxifen, toremifene. |
3. |
Other anti-estrogenic substances including, but not limited to : clomiphene, cyclofenil, fulvestrant. |
4. |
Agents modifying myostatin function(s) including but not limited to: myostatin inhibitors. |
S5. |
DIURETICS AND OTHER MASKING AGENTS Masking agents are prohibited. |
They include: Diuretics, probenecid, plasma expanders ( e.g. |
intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol ) and other substances with similar biological effect(s). |
Diuretics include: Acetazolamide, amiloride, bumetanide, can renone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazo ne, spironolactone, thiazides (e.g. |
bendroflumethiazide, chlorothiazide, hydrochlorothiazide) , triamterene, and other substances with a similar chemical struct ure or similar biological effect(s) (except drosperinone and topical dorzolamide and brinzolamide which are not prohibited). |
[Comment to class S5: A Therapeutic Use Exemption is not valid if an Athlete ’s urine contains a diuretic in associ ation with threshold or sub-th reshold levels of an exogenous Prohibited Substance(s). ] |
PROHIBITED METHODS M1. |
ENHANCEMENT OF OXYGEN TRANSFER The following are prohibited: 1. |
Blood doping, including the use of autologous , homologous or heterologous blood or red blood cell products of any origin; 2. |
Artificially enhancing the uptake, tran sport or delivery of oxygen, including but not limited to perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. |
haemogl obin-based blood substitutes, microencapsulated haemoglobin products). |
M2. |
CHEMICAL AND PHYSICAL MANIPULATION 1. |
Tampering, or attempting to tamper, in order to alter the integrity and validity of Samples collected during Doping Controls is prohibited. |
These include but are not limited to catheterization, urin e substitution and/or alteration. |
2. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.